My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

446.40 -3.18 (-0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 814,464
Open 453.05
Bid (Size) 442.00 (1)
Ask (Size) 500.00 (1)
Prev. Close 449.58
Today's Range 442.51 - 453.05
52wk Range 205.87 - 484.21
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam... 
Via Benzinga
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade

Performance

YTD
+91.1%
+91.1%
1 Month
-1.7%
-1.7%
3 Month
+38.3%
+38.3%
6 Month
+66.3%
+66.3%
1 Year
+62.6%
+62.6%

More News

Read More
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
Via Benzinga
Beyond The Numbers: 28 Analysts Discuss Alnylam Pharmaceuticals Stock
Via Benzinga
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
Via Benzinga
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics
Via Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
Via Benzinga
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
Via Benzinga
Demystifying Alnylam Pharmaceuticals: Insights From 19 Analyst Reviews
Via Benzinga
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Reddit, Wingstop, And Generac Are Among Top 10 Large Cap Gainers Last Week (July 28-August 1): Are The Others In Your Portfolio?
Via Benzinga
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Via Benzinga
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
Via Benzinga
Topics Earnings
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday
Via Benzinga

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 446.40
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 09/26/25 04:00 PM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 53.05B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 53B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.